Cardinal Health, Inc. (CAH) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Zacks analysts have upgraded Cardinal Health to a buy rating, citing confidence in the company’s recent performance and outlook. The upgrade follows the company’s strong financial results and forward guidance, which suggest continued revenue growth and margin expansion. This positive rating signals that analysts expect the stock to outperform peers in the near term. The upgrade may attract new investors looking for exposure to a health‑care distributor with solid fundamentals. As a result, the market may see increased demand for CAH shares over the next 1–10 trading days. The primary driver behind the rating is the company’s robust earnings trajectory and optimistic outlook. Investors should monitor the upcoming earnings release for confirmation of these trends and any updates to guidance. A surprise downgrade or weaker‑than‑expected earnings could quickly reverse the positive sentiment. Therefore, watch the earnings call and any subsequent analyst commentary for signals that could alter the buy recommendation.

CAH|Company Info

Sector

Healthcare

Industry

Medical Distribution

Exchange

NYQ

Country

United States

Website

cardinalhealth.com

Symbol

CAH

Description

Cardinal Health, Inc. is a global healthcare company specializing in the distribution of pharmaceuticals and medical products, serving a diverse customer base across the healthcare spectrum. The company's core business revolves around two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Cardinal Health offers a comprehensive suite of services, including the distribution of branded and generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter products, alongside a wide array of medical, surgical, and laboratory supplies. Furthermore, the company provides essential services such as pharmacy management, radiopharmaceutical preparation, and supply chain solutions, solidifying its position as a critical partner for healthcare providers and pharmaceutical manufacturers. Incorporated in 1979 and headquartered in Dublin, Ohio, Cardinal Health plays a vital role in the healthcare industry by connecting manufacturers with providers and patients.

CAH|Earnings Snapshot

Earnings Summary

Cardinal Health, headquartered in Dublin, Ohio, operates as a global healthcare distributor, providing pharmaceuticals and medical products across two main segments—Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution—serving hospitals, pharmacies, and other healthcare providers. The medical distribution industry is characterized by tight margins and evolving reimbursement policies. In the most recent two quarters, Cardinal’s Q3 2025 EPS of $2.55 beat the $2.16845 estimate while revenue climbed to $64.009 B from $60.159 B in Q2 2025, marking a 6.5 % YoY increase; the prior two quarters saw Q1 2025 EPS of $2.35 beating the $2.14886 estimate and revenue of $54.878 B, a modest decline from Q4 2024’s $55.264 B. Thus, the company has consistently outperformed earnings estimates in all four quarters, with revenue growth accelerating in 2025 but a slight dip in Q3 2026 to $60.94 B versus $64.009 B in Q3 2025. Historically, Cardinal has maintained a streak of EPS beats and has shown resilient revenue growth, though the 2026 quarter indicates a modest slowdown. Recent news reports a robust upside outlook, with analysts projecting a 30.58 % lift in full‑year earnings and a 15.12 % rise in revenue, driven by strong cost control and margin expansion; meanwhile, the removal from defensive indices and an Evercore upgrade to a $265 price target underscore a positive sentiment shift. Investors should watch for the upcoming earnings release to confirm guidance on revenue, margin trends, and supply‑chain dynamics, and to assess whether pricing power remains intact amid regulatory and reimbursement pressures. The key will be whether Cardinal can sustain its margin expansion while navigating potential cost‑inflation and maintaining its distribution network efficiency.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q4'26	$2.42	-	-
Q3'26	$2.82	$3.17	+12.5%
Q3'25	$2.17	$2.55	+17.6%
Q2'25	$2.03	$2.08	+2.4%
Q1'25	$2.15	$2.35	+9.4%
Q4'24	$1.76	$1.93	+9.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q4'26	$65.9B	-	-
Q3'26	$62.3B	$60.9B	-2.2%
Q3'25	-	$64.0B	-
Q2'25	-	$60.2B	-
Q1'25	-	$54.9B	-
Q4'24	-	$55.3B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

CAH Stock Snapshot

CAH is currently trading at $235.80, giving Cardinal Health, Inc. a market cap of 55.17B and a P/E ratio of 35.5. Today's range spans $232.05–$236.26, with shares opening at $233.07 and moving up $0.18 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 60/100.

Over the past year CAH has traded between $137.75 and $243.21 - the current price is +71.2% off the 52-week low and -3.0% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $249.60 (range $215.00–$275.00), implying upside of +5.9%.

Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and CAH (55.17B market cap) with a BUY read (86/100) and bullish sentiment (60/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 35.5. Price: $235.80 (near 52-week highs in $137.75–$243.21). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (60/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $235.80 (near 52-week highs), CAH's position within the $137.75–$243.21 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

60/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Brokerage consensus rates Cardinal Health (CAH) as a Buy, yet analysts warn that the recommendation may be overly optimistic and its usefulness is questionable. The rating reflects positive expectations for the company’s performance, but investors should consider the potential overstatement of upside. Key drivers include the company’s growth prospects and market positioning, while the recommendation’s reliability remains uncertain.

What did this article say?

TD Cowen has lifted its price target for Cardinal Health from $255 to $275, reflecting a more bullish outlook on the company’s earnings prospects. The upgrade follows a review of CAH’s recent financials and a reassessment of its growth trajectory. The new target suggests analysts expect stronger revenue and margin expansion in the coming quarters.

What did this article say?

TD Cowen analyst Charles Rhyee maintains a Buy recommendation for Cardinal Health (CAH) and raises the price target from $255 to $275. The upgrade reflects confidence in the company’s earnings outlook and operational performance. This positive stance signals potential upside for investors holding or considering CAH shares.

What did this article say?

Cardinal Health (CAH) will publish its fiscal 2026 fourth‑quarter and year‑end results on August 11, ahead of NYSE opening. The company will host a webcast of the earnings discussion at 8:30 a.m. Eastern, providing investors with real‑time commentary. The release will include a slide deck and replay available for 12 months on the Investor Relations site. This schedule sets expectations for earnings guidance, margin outlook, and any updates on supply‑chain or regulatory matters. Traders should note the pre‑market release timing and the potential impact of any disclosed guidance revisions. The webcast offers an opportunity to gauge management sentiment and Q&A insights that could influence short‑term price action.

What did this article say?

Cardinal Health (CAH) slipped 1.07% in the latest session, lagging the broader market. Analysts project a Q1 EPS of $2.41, a 15.87% year‑over‑year increase, and revenue of $65.61 billion, up 9.06% from the prior year. Full‑year guidance shows earnings rising 30.58% and revenue 15.12% versus 2023. Investors should watch the upcoming earnings release and any analyst estimate revisions for potential catalysts.

What did this article say?

Cardinal Health’s removal from the Russell 1000 defensive indices in late June 2026 coincided with robust earnings, including $60.94 billion in revenue and $399 million in net profit. Despite the index change, analysts continue to view the company favorably, citing steady demand for drug distribution and medical products. The core earnings drivers remain strong, though investors may reclassify the stock. Traders should keep an eye on future guidance and any regulatory or pricing risk developments.

What did this article say?

Evercore ISI has lifted its price target for Cardinal Health (CAH) to $265 from $240, reflecting a more optimistic view of the company’s prospects. The brokerage maintains a buy rating and cites a mean target of $249.93 based on its analysis. The upgrade suggests that analysts expect stronger earnings and margin expansion in the near term. Investors should watch for CAH’s upcoming earnings release and any regulatory updates that could impact its product pipeline.

What did this article say?

Cardinal Health receives a Buy rating from SeekingAlpha, citing defensive business fundamentals and robust adjusted EPS growth. The rating underscores the company’s resilient distribution network and cost efficiencies. The analysis highlights CAH’s ability to maintain stable margins amid industry pressures. Investors may view this as a bullish signal for the healthcare distributor. The rating could support a positive outlook for CAH’s stock performance.

What did this article say?

B of A Securities analyst Allen Lutz has kept a Buy rating on Cardinal Health (CAH) while lifting the price target from $240 to $260. The upgrade signals a bullish stance on CAH’s near‑term prospects. Traders should monitor the upcoming earnings report for guidance and any updates on product pipelines or regulatory approvals that could influence the stock’s trajectory.

What did this article say?

Cardinal Health’s stock recently rallied, exceeding early expectations, yet analysts have moved the rating to a hold. The downgrade reflects concerns over margin compression and competitive pressure in the drug distribution space. Investors should evaluate the company’s cost‑control initiatives and the impact of its recent contract negotiations. The market’s reaction underscores the need to monitor earnings guidance and supply‑chain dynamics.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

CAH·Cardinal Health, Inc.

EPS

Revenue

CAH Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More